A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
Home AIMD Business Boston Scientific Q1 2012 AIMD Results: CRM Down 10%, Neuromodulation 8% Up
formats

Boston Scientific Q1 2012 AIMD Results: CRM Down 10%, Neuromodulation 8% Up

Boston Scientific LogoYesterday Boston Scientific announced financial results for the first quarter ended March 31, 2012.  Sales of Cardiac Rhythm Management devices were $501M vs. $559M for Q1 a year ago, or a decrease of 10%.  Sales of  Neuromodulation devices increased by 8% a year ago from $77M to $84M for Q1.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific Q1 2012 AIMD Results: CRM Down 10%, Neuromodulation 8% Up  comments